$FDMT News

B. Riley Securities Initiates Coverage On 4D Molecular Therapeutics with Buy Rating, Announces Price Target of $37

4D Molecular's One-Shot Eye Therapy Delivers Two-Year Win

HC Wainwright & Co. Reiterates Buy on 4D Molecular Therapeutics, Maintains $36 Price Target

Reported Saturday, 4D Molecular Therapeutics' 4D-150 Achieves 78% Overall Treatment Burden Reduction At 2 Years, With 87% Reduction In Recently Diagnosed Wet Age-Related Macular Degeneration Subgroup

4DMT Announces Positive 2-Year Data from PRISM Phase 2b Clinical Trial in a Broad Wet AMD Population

4DMT Announces New Employment Inducement Grants

4DMT Announces Presentation at 44th Annual Scientific Meeting of the American Society of Retina Specialists

4DMT Completes Enrollment for 4FRONT-2 Global Phase 3 Clinical Trial of 4D-150 in Wet AMD

4D Molecular Therapeutics Completes Enrollment For Its 4FRONT-2 Second Phase 3 Clinical Trial Evaluating 4D-150 In Patients With Wet Age-Related Macular Degeneration

4DMT Announces New Employment Inducement Grants

4D Molecular Therapeutics, Inc. (FDMT) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

4D Molecular Therapeutics, Inc. (FDMT) Presents at Jefferies Global Healthcare Conference 2026 Transcript

4DMT to Participate in Upcoming Investor Conferences

4D Molecular Therapeutics, Inc. (FDMT) Presents at RBC Capital Markets Global Healthcare Conference 2026 Transcript

4D Molecular Therapeutics Inc (FDMT): Gene Therapy Stock Made for You?

4D Molecular Therapeutics Touts Rapid Phase 3 Momentum for Retinal Gene Therapy

4DMT Announces New Employment Inducement Grants

4D Molecular Therapeutics, Inc. (FDMT) Presents at Bank of America Global Healthcare Conference 2026 Transcript

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Just Released Its First-Quarter Results And Analysts Are Updating Their Estimates

4D Molecular Therapeutics (NASDAQ:FDMT) Q1 2026: Revenue Miss and Wider Losses Overshadow Phase 3 Progress